Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR plus chemotherapy in non-functioning endocrine pancreatic tumors
2008-003594-41Phase 2Terminated
- Sponsor
- Akademiska sjukhuset
- Start
- Oct 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in nonfunctional pancreatic neuroendocrine tumor (NF-PNET), sponsored by Akademiska sjukhuset. Primary endpoint: Time to progression. Started Oct 2008; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
nonfunctional pancreatic neuroendocrine tumor (NF-PNET)
Beyond the preview
Go deeper on 2008-003594-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003594-41.